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Arterial calcification in  
chronic kidney disease: key roles  
for calcium and phosphate
Shanahan et al., Circ Res 2011; 109: 697–711; doi:10.1161/
CIRCRESAHA.110.234914
The central role of phosphate in the development of vascular cal­
cification (VC) has been documented in vitro (vascular smooth 
muscle cells), in vivo (several experimental animal models), and 
in careful epidemiological studies in patients with normal renal 
function and progressive renal failure. Research has shown that 
dialysis patients are particularly prone to develop VC, possibly 
because of simultaneous severe dysregulation of calcium (Ca) 
and phosphate (P) metabolism, retention and accumulation of 
many substances cleared by the kidneys under normal condi­
tions, and downregulation of factors protecting against VC in 
this group of patients. In a recent and excellent review, Shanahan 
and colleagues describe the physiological regulatory mechanisms 
for Ca and P homeostasis and the basis for their dysregulation 
in chronic kidney disease (CKD). In addition, they highlight 
recent findings indicating that elevated Ca and P have direct 
effects on vascular smooth muscle cells (VSMCs) that promote 
VC, including stimulation of osteogenic/chondrogenic differ­
entiation, vesicle release, apoptosis, loss of inhibitors, and extra­
cellular matrix degradation. These studies suggest a major role for 
elevated P in promoting osteogenic/chondrogenic differentiation 
of VSMCs, whereas elevated Ca has a predominant role in pro­
moting VSMC apoptosis and vesicle release. Furthermore, the 
effects of elevated Ca and P are synergistic, providing a major 
stimulus for VC in CKD. Unraveling the complex regulatory 
pathways that mediate the effects of both Ca and P (see Figure 
for that of P) on VSMCs will ultimately provide novel targets and 
therapies to limit the destructive effects of vascular calcification 
in CKD patients.
Marc De Broe
Proteinase-activated receptors 1 
and 2 exert opposite effects  
on renal renin release
Höcherl et al., Hypertension 2011; 58: 611–618; doi:10.1161/
HYPERTENSIONAHA.111.173229
Proteinase­activated receptors (PARs) belong to a family of 
G protein­coupled receptors that, as their name indicates, are 
activated by serine proteases such as trypsin and thrombin that 
cleave their extracellular N­terminus. This exposes a sequence 
that acts as a tethered activating ligand by binding to an extracel­
lular loop of the receptor and inducing its autoactivation. To date, 
four types of PARs have been described, PAR1, PAR2, PAR3, 
and PAR4. Thrombin activates PAR1, PAR3, and PAR4. PAR1 
can also be activated by matrix metalloproteinase 1, plasmin, 
and activated protein C. PAR2 is activated by trypsin, tryptase, 
and kallikreins. Because of their many actions, PARs are believed 
to play critical roles in vascular homeostasis, coagulation, and 
inflammation. For example, PAR1 mediates thrombin­induced 
platelet aggregation, cell proliferation, and vascular contractility, 
while PAR2 is involved in control of vascular tone. All four PARs 
are expressed within the kidney, and by immunohistochemis­
try, PAR1 and PAR2 were located in renal vascular and tubular 
cells. Moreover, PAR1 activation caused renal vasoconstriction 
and reduced glomerular filtration rate, whereas PAR2 activation 
caused vasodilation and increased glomerular filtration rate in 
isolated perfused rat kidneys preconstricted with angiotensin 
II. As it was previously found that systemic administration of 
exogenous thrombin reduced plasma renin, Höcherl et al. exam­
ined whether PARs regulate renin release. They used mouse kid­
neys perfused ex situ at a constant perfusion pressure of 90 mm 
Hg. During enhanced renin secretion by administration of the 
b­adrenoreceptor agonist isoproterenol, thrombin induced renal 
vasoconstriction and reduction in the secretion of renin; block­
ade of PAR1 with an antagonist had no effect on the former, but 
it abolished the inhibition of renin secretion induced by throm­
bin. Conversely, activation of PAR1 by a synthetic peptide that 
corresponds to its tethered ligand after proteolysis also caused 
vasoconstriction and inhibition of renin secretion. The inhibition 
of renin secretion by PAR1 activation was also found when the 
secretion was stimulated by prostaglandin E2, by bumetanide, 
or by reduction of perfusion pressure. However, the enhanced 
renin release due to hypocalcemia was unaffected by activation 
of PAR1. The authors also found that, in contrast to the results 
with PAR1 activation, activation of PAR2 increased renin release. 
By immunofluorescence (Figure), PAR1 was found in association 
Role of phosphate in VSMC calcification. Elevated extracellular 
phosphate (P) affects multiple signaling pathways that increase the 
susceptibility of VSMCs to calcification, including decreased calcification 
inhibitors, increased extracellular matrix (ECM) degradation, osteogenic/
chondrogenic differentiation, apoptosis, and vesicle release. Some of the 
effects of P are mediated through the sodium-dependent phosphate 
cotransporters PiT-1 and PiT-2, potentially via P transport-dependent and 
P transport-independent activities. Whether other receptors exist that 
mediate specific downstream signaling pathways in response to P is not 
yet known, but the possibility cannot be excluded.
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with juxtaglomerular cells, as was PAR2, which was also located 
in preglomerular vessels and inside the glomerulus. These results 
indicate that PAR1 and PAR2 are likely important regulators of 
renin secretion, thus providing a novel target for the regulation 
of this important function.
Juan Oliver
Novel roles for regulatory  
T cells in inflammation
Maganto-García et al., J Immunol 2011; 187: 3521–3529; doi:10.4049/
jimmunol.1003947
The identification of regulatory T cells (Tregs) and their role 
in tissue injury via mitigation of inflammation and progressive 
disease, including in kidney diseases and renal transplanta­
tion, has been one of the major developments in immunology 
during the past decade. The ability of Tregs to traffic to sites 
of inflammation supports the idea that adoptive transfer of in 
vitro­expanded human Tregs could be used for treatment of 
immune and inflammatory diseases. Recently, Maganto­García 
et al. explored the possibility that Tregs may have direct anti­
inflammatory influences on tissues by mitigating endothelial 
activation, in a manner independent of their well­established 
suppressive effects on lymphocytes. The authors studied the 
interactions between mouse Tregs and endothelial cells, the 
first site of Treg interaction during acute inflammation, as well 
as the influence of Tregs on endothelial function. They show 
that Foxp3+ adaptive/inducible Tregs (iTregs), but not naturally 
occurring Tregs, efficiently interact with endothelial selectins 
and transmigrate through endothelial monolayers in vitro. 
In response to activation by endothelial antigen presentation 
or immobilized anti­CD3e, Foxp3+ iTregs suppressed tumor 
necrosis factor­a­ and interleukin­1b­mediated endothelial 
selectin expression and adhesiveness of effector T cells. This 
suppression was contact independent and rapidly acting and 
was mediated by transforming growth factor­b­induced activin 
receptor–like kinase 5 signaling in endothelial cells. In addition, 
Foxp3+ iTregs adhered to inflamed endothelium in vivo, and 
their secretion products blocked acute inflammation in a model 
of peritonitis. These data support the concept that Foxp3+ iTregs 
help to regulate inflammation independently of their influence 
on effector T cells by direct suppression of endothelial activation 
and leukocyte recruitment. These observations may be of par­
ticular interest for the potential of therapeutic, adoptive transfer 
of Tregs into solid­organ transplants, as it would decrease the 
initial activation of the endothelium in the donor organ.
Detlef Schlöndorff
Phosphate may promote  
CKD progression and attenuate  
the renoprotective effect  
of ACE inhibition
Zoccali et al., J Am Soc Nephrol 2011; 22: 1923–1930; doi:10.1681/
ASN.2011020175
The benefit of angiotensin­converting enzyme (ACE) inhibitors 
for the progression of CKD has been demonstrated in many ran­
domized trials, including the Ramipril Efficacy in Nephropathy 
(REIN) study, in which 352 patients with chronic progressive 
nephropathies were randomized to ramipril versus placebo.1 A 
secondary analysis of the REIN study analyzes the interaction 
between treatment with the ACE inhibitor and serum phosphate 
levels given the new understanding of the potential role of phos­
phate and fibroblast growth factor­23 in CKD progression. Sub­
jects were stratified by quartile of serum phosphate. In general, 
subjects with greater serum phosphate levels had lower glomer­
ular filtration rate (GFR) and hemoglobin measures, although 
within the quartile of phosphate, there were no differences in 
clinical and demographic parameters based on treatment group. 
Participants in the upper quartiles of phosphate measurement 
progressed to end­stage renal disease (ESRD) or the composite 
of ESRD and doubling of creatinine at a significantly greater 
rate. In univariate analyses, an increase in serum phosphate by 1 
mg/dl was associated with an increased hazard of progression to 
ESRD (hazard ratio (HR) 3.30). When controlled for other pre­
dictors of CKD progression, including baseline GFR and urinary 
protein excretion, the hazard associated with higher phosphate 
was attenuated but still significant (HR 1.84). Phosphate inter­
acted with treatment group in both univariate and multivariable 
analyses. In the univariate analysis, treatment with ramipril was 
associated with a decreased hazard of ESRD in the lower three 
quartiles of phosphate, although the decrease was attenuated in 
the third (HR 0.13 in the first and second and 0.32 in the third). 
Treatment group was not associated with a decreased risk of pro­
gression to CKD in the quartile of participants with the highest 
serum phosphate levels (HR 0.82).
It has been hypothesized that phosphate plays a role in the 
progression of CKD. These results suggest that this role may be 
strong enough to limit or blunt the renoprotective effect of ACE 
inhibitor therapy. 
Lynda Szczech
1Lancet 1997; 349: 1857–1863.
Immunoreactivity of PAR1, PAR2, and renin in sections of a mouse 
kidney. (a) PAR1 alone (green); (b and e) renin alone (red); (c) PAR1 and renin; 
(d) PAR2 alone (green); (f) PAR2 and renin. *PAR1 or PAR2 staining. Arrows 
indicate regions with PAR1/renin or PAR2/renin coexpression (yellow).
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